| Bioactivity | Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria[1]. |
| Invitro | Telavancin has a rapid, concentration-dependent bactericidal effect, due to disruption of cell membrane integrity[1].Telavancin (5 μg/mL) exerts bacteriocidal effect against a MRSA strain (COL) and a VISA strain (HIP5836) at a concentration of 5 µg/mL[1]. |
| Name | Telavancin |
| CAS | 372151-71-8 |
| Formula | C80H106Cl2N11O27P |
| Molar Mass | 1755.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Telavancin
CAS: 372151-71-8 F: C80H106Cl2N11O27P W: 1755.63
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.